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Meta-analysis of Randomized Trials Comparing Drug-Coated Balloon with
Drug-Eluting Stent for Treatment of Coronary in-Stent Restenosis
Alban Dibra1, Laureta Dibra1, Elvis Pavli1
1University Hospital Center, Tirana, Albania
Background: Drug-coated balloon (DCB) has been proposed as an alternative to
drug-eluting stent (DES) for treatment of coronary in-stent restenosis (ISR). Several
studies have examined the relative performance of these devices. However, their
statistical power regarding the evaluation of clinical endpoints has been limited due to
their small sample size. Therefore, we performed a meta-analysis of randomized trials
comparing DCB with DES in patients with ISR.
Methods: We searched for randomized trials comparing DCB with DES with no less
than 6 month follow-up. We excluded studies in which a BMS was used in conjunction
with DCB. Outcomes of interest were repeat revascularization, death, myocardial
infarction and the occurrence of major cardiac events (MACE). Odds ratios (ORs) with
95% conﬁdence intervals (CIs) were computed as summary statistics.
Results: Five studies were included in this meta-analysis. In all studies, the DCB
consisted of a paclitaxel-coated balloon while the DES was either a paclitaxel-eluting
or an everolimus-eluting stent. There were no differences regarding the two treatment
modalities regarding the odds of repeat revascularization [OR 0.92 (95% CI 0.63 to
1.33)], death [OR 0.81 (95% CI 0.32 to 2.05)] or myocardial infarction [OR 0.90 (95%
CI 0.36 to 2.21)]. Similarly, patients treated with DCB and DES had comparable odds
of suffering a MACE [OR 1.05 (95% CI 0.72 to 1.54)].
Conclusions: Among patients with coronary ISR, treatment with DCB is associated
with similar efﬁcacy and safety proﬁle compared to treatment with DES.
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Systematic treatment of the side branch in a bifurcation lesion with a new drug
eluting balloon:the DEBSIDE study.
jacques berland1, PATRICE GUERIN2, Thierry Lefevre3, Jean Fajadet4
1clinique saint hilaire, rouen, France, 2HOPITAL GUILLAUME ET RENE
LAENNEC, NANTES, France, 3ICPS, Massy, France, 4CLINIQUE PASTEUR,
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Background: The optimal treatment of the side branch(SB) in a bifurcation coronary
lesion is still a debate.Presently no study have evaluated the role of drug eluting balloon
SB infation after placement of a drug eluting stent in the main branch(MB). The DAN-
UBIO balloon integrates Speed Pax technology combining an excipient(BTHC)with
Paclitaxel(2.5mg/mm2) The DEBSIDE study is a prospective non randomized multi-
center study evaluating the DANUBIO balloon for the treatment of a SB(SB>2mm
diameter)after placement of a dedicated Paclitaxel stent(NILE Pax)in the MB.
Methods: From 8 French centers,50 patients(male 79%,Diabetic 26%,acute coronary
syndrome 22%) with bifurcation lesion were enrolled.After balloon pre-dilatation,
placement of the Nile Pax stent and kissing inﬂation(80%)without signiﬁcant residual
dissection, a DANUBIO balloon according to the SB size was inﬂated for 30s at 9.52.1
atm . Coronary angiography pre procedure before and after DANUBIO inﬂation and at 6
months were recorded and analysed by an independent core laboratory.Clinical follow up
was scheduled at 1,6 and 12 months. The primary endpoint involved 6 months late
loss(LL) of the ostiumof theSB and secondary endpointsMBLL,binary restenosis rate of
SB andMBand clinically driven revascularisation rates formain and secondary branches.
Results: Bifurcation lesions reached LAD/diag 74%,Circumﬂex/marginal 18% and
distal right coronary in 8%.Signiﬁcant SB lesion(Medina 111,101,011) was noted in
62% of the patients.Procedural success rate reached 100% after 3 additional stents in
the main branch .Per protocol no additional stent was placed in the SB. 2 patients
without cardiac events did not accept the angiographic control For the 48 others(96%)
at 6 month the minimal luminal diameter of the SB(1.580.34mm)was identical to the
post procedure one(1.530.3mm)resulting in a very low LL of 0.00650.4mm.
Accordingly the SB target lesion revascularisation(TLR) rate reached only 2%. For the
MB speciﬁcally the TLR reached 8% and 2 patients got non Target vessel angioplasty.
Conclusions: Combining the DANUBIO balloon with a dedicated bifurcation stent
seems to be a very effective strategy and needs to be conﬁrmed in a larger study.
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Results Of Percutaneous Coronary Intervention With Sequent Please Paclitaxel
Eluting Balloon Catheter At A Very Long-Term Follow-Up.
Ignacio Sanchez-Perez1, Alfonso Jurado-Roman1, Manuel Marina-Breysse1,
Natalia Pinilla1, Maria T. Lopez-Lluva1, Jesus Piqueras-Flores1, Javier Benezet2,
Fernando Lozano1
1Hospital General Universitario de Ciudad Real, Ciudad Real, Spain, 2Hospital
Universitario de Jerez, Jerez de la Frontera, Cadiz
Background: Drug eluting balloons currently constitute one of the therapeutic tools
used in percutaneous coronary intervention (PCI) of both stent restenosis and de novo
coronary lesions, mainly in bifurcations and small vessels. Nowadays, their results at a
very long-term follow up are unclear. The main objective of this study was to evaluate
the efﬁcacy and safety of second-generation Sequent Please paclitaxel eluting
balloon (PEB) at 5 years.
Methods: We prospectively included 157 consecutive patients (6912 years, 71.3%
male) with 191 lesions (de novo or restenosis) treated with PEB between May 2009
and April 2013. We evaluated the presence of major cardiac events (MACE) after aB82 JACC Vol 64/11/Suppl B j September 13–17,prolonged clinical follow-up (median 36 months): death, nonfatal myocardial
infarction, target lesion revascularization (TLR ) and thrombosis.
Results: 40.8% of patients had stable coronary artery disease and 58.2% acute cor-
onary syndromes (46.6% Non-STEMI and 12.7% STEMI). 50.3% of patients were
diabetic and 24.3% of the lesions were bifurcations. Of the 191 lesions, 79 were de
novo lesions and 110 restenosis [77 restenosis of bare metal stent (BMS) and 33 of
drug-eluting stents (DES)]. 87.8% of the lesions were treated with PEB, 9.5% with
PEB and BMS and 2.6% with PEB and DES. There were no signiﬁcant differences
regarding baseline characteristics of these three groups neither in the MACE rate after
a long-term follow-up (p¼0.545). During follow-up, 10 patients died (2 cardiovas-
cular and 8 non-cardiovascular deaths) and a TLR rate of 2.6% was observed. No
cases of thrombosis were observed, immediately after the procedure nor during
follow-up. 20.1% of patients had an angiographic follow-up. We observed a higher
need for additional stent after dissection due to PEB in de novo lesions (p¼0.045) and
especially in diffuse lesions (p¼0.048) and bifurcations (p¼0.026).
Conclusions: Percutaneous coronary intervention of de novo coronary lesions and in-
stent restenosis (both of BMS and DES) with Sequent Please PEB provide very
favorable results at a very long-term follow up.
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Synergy of Drug Coated Balloons plus Second-generation Drug Eluting Stents in
lesions with high risk for restenosis
Hiroyoshi Kawamoto1, Azeem Latib2, Katsumasa Sato1, Tadashi Miyazaki1,
Vasileios F. Panoulas2, Filippo Figini2, Alaide Chieffo2, Matteo Montorfano2,
Mauro Carlino2, Antonio Colombo1
1EMO GVM Centro Cuore Columbus/San Raffaele Scientiﬁc Institute, Milan, Italy,
2San Raffaele Scientiﬁc Institute, Milan, Italy
Background: Limited data are available as to whether the combination of drug coated
balloons (DCB) plus drug eluting stents (DES) would be more efﬁcacious than DES in
lesions or patients at high risk for restenosis. A combination of paclitaxel (present in
coated balloons) and a limus drug may exert a synergistic effect in preventing major
adverse cardiac events (MACE). We report the long-term follow-up data from a real-
world cohort.
Methods: Between 2009 and 2013, 68 patients (82 lesions) were treated with a
combination of DCB and implantation of a second-generation DES. The study end-
points were MACE, deﬁned as all-cause death, myocardial infarction (MI), and target
vessel revascularization (TVR). Furthermore, individual parameters, including cardiac
death, MI, TLR and TVR during the follow-up period, were evaluated. Cox regression
analysis was performed to determine the independent predictors of MACE.
Results: In our study cohort, baselines patient characteristics were severe. The cohort
had 31 lesions with in-stent restenosis (ISR) (37.8%), 18 lesions (22%) with multiple
ISR (more than 2 times) and 23 patients with diabetes mellitus (DM) (34.3%). The
mean lesion length was 25.8  13.7 mm, and 13% were CTO lesions. At median
follow-up of 19.8 months, (interquartile range [IQR]: 11.5–80.4), the MACE rates
were 9.2 and 27.4% at 1 and 2 years, respectively. The TLR and TVR rates at 1 year
were 5.9 and 13.5%, respectively. After 1-year, these rates increased to 24.7% and
32.5%. Very late stent thrombosis occurred in 1 patient on 1036 days after PCI. The
ﬁnal Cox regression model identiﬁed only insulin-dependent DM as the independent
predictor of MACE [HR 5.16, (95% CI, 1.04–25.6); P ¼ 0.05].
Conclusions: In our study, dual drugs with DCB and DES in lesions with high risk for
restenosis may be synergistic that may explain the favorable outcome. Insulin-
dependent DM was only the independent predictor of MACE. A large randomized
study is essential to evaluate the efﬁcacy of DCB plus DES combination in selected
high-risk lesions for restenosis.
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Rotenburg a.d.F., Germany, 7BBraun Melsungen, Berlin, Germany, 8Technische
Universität Dresden, Herzzentrum Dresden, Universitätsklinik Dresden, Dresden,
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Background: The standard treatment of bifurcation lesions is application of a drug
eluting stent to the main branch with provisional side branch stenting. While this
resulted in considerable improvement in overall MACE rate suboptimal side branch
results remained a problem. Given the good results of drug coated balloons (DCB) in
small vessels, we set out to explore the beneﬁt of distal main or side branch treatment
with a DCB and compared this to regular balloon angioplasty (POBA).
Methods: The study was performed from 2011 to 2013 in 6 German centers. All
patients planned for elective or deferred treatment of lesions involving bifurcations
were screened for participation in the trial. Native bifurcation lesions were included if
side branch vessel diameter was >2 mm and 3.5 mm and no proximal main branch
lesions was found. After successfull predilatation (TIMI III ﬂow, recoil 30 %,
dissection not beyond B according to NHLBI classiﬁcation) randomization was2014 j TCT Abstracts/Drug-Eluting Balloons and Local Drug Delivery
Devices
Sample
Size
Average Paclitaxel Conc.
(ng/cm2)
Standard
deviation p value
Lutonix 21 0.34 0.27 <0.001
Medtronic 18 20.39 17.15
www.jacctctabstracts2014.com SATURDAY, SEPTEMBER 13, 2014, 5:00 PM–7:00 PMperformed to either DCB application or no further treatment. Provisional stenting was
discouraged but allowed in both groups. Follow-up angiograms were done after 9
months. For quantitative coronary angiographic analysis CAAS II was used. Primary
efﬁcacy endpoint was late lumen loss (LLL).
Results: 64 patients were randomized to DCB or POBA treatment. Minimal lumen
diameter (0.58  0.22 mm) and grade of stenosis (76.3  8.7 %) were equal in both
groups. Only 5 stents were used as bail out. Angiographic follow-up was achieved in
75 % of patients. The remaining 25 % had telephone follow-up. No patient was lost to
follow-up, no patient died. There was 1 non ST-elevation myocardial infarction in the
POBA group. Restenosis rate was 25 % in the POBA group vs. 6 % in the DCB group
(p¼0.08). Target lesion revascularization was necessary in 3 patients of the POBA vs.
1 patient of the DCB group. The primary endpoint LLL was 0.15 mm in the DCB vs.
0.48 mm in the POBA group (p¼0.035).
Conclusions: Our results underscore the potential of DCBs as stand alone therapy for
bifurcation lesions. Therefore, in bifurcation lesions that show only class A or B
dissection according to the NHLBI classiﬁcation and recoil not beyond 30 % the use
of DCBs is a sound strategy.
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Treatment Of Coronary In-Stent Restenosis With Paclitaxel-Coated Balloon
Catheter: 36- Month Clinical Results
Javier Benezet1, Santiago Camacho-Freire1, Alejandro Gutierrez-Barrios1,
Antonio Agarrado1, Jesus Oneto1
1Hospital Universitario de Jerez, Jerez de la Frontera, Cadiz
Background: Paclitaxel-coated balloons (PCB) have been proven to be effective for
the treatment of coronary in-stent restenosis (ISR) after bare-metal stent (BMS) or
drug-eluting stent (DES) implantation. This study aims to evaluate the long-term
safety and efﬁcacy of the second-generation SeQuent Please PCB in coronary ISR in
routine real-world practice.
Methods: Between May 2009 and February 2011, all consecutive patients with ISR
lesions treated with the SeQuent Please PCB at our institution were prospectively
included. Patients were followed up for 36 months by clinical observation. The primary
endpoint was the clinically driven target lesion revascularization (TLR) rate at 36
months. The secondary endpoint was the rate of major adverse cardiac events (MACE:
deﬁned as a composite of cardiac death, myocardial infarction, and TLR) at 36 months.
Results: 63 patients with 73 ISR lesions (39 BMS, 34 DES) were included. Mean age
was 67.411.7 years. 77.8 % were male and 55.6 % were diabetics. The majority of
patients presented with stable angina (61.9 %). The target lesion was mainly located in
the right coronary artery (42.5%) and the left anterior descending coronary artery
(38.4%). The mean reference vessel diameter was 3.00.5 mm and the mean target
lesion length was 19.7  6.6 mm. Procedural success was 100 %. Coronary dissection
occurred in 2 patients (3.2 %), requiring additional stent implantation. Follow-up rate
was 92.1 %. The TLR rate was 4.8 % after 36 months. Cumulative MACE at 36
months was 11.1 %, with 4.8 % cardiac death and 3.2 % myocardial infarction. No
vessel thrombosis was documented. The TLR rate did not differ for PCB angioplasty
for BMS-ISR compared with DES-ISR (2.9 % vs. 7.1%, p¼0.58). Baseline lesion
characteristics and procedural data did not differ except for a longer lesion length for
BMS-ISR compared with DES-ISR (21.76.0 mm vs. 17.36.5 mm, p¼0.004).
Conclusions: Treatment of coronary ISR with the second-generation SeQuent Please
PCB provides good clinical outcomes demonstrated by the low TLR rate and low
MACE rates at long-term follow-up.
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Safety Evaluation of Paclitaxel Coated Balloon as a “Same-Drug” and
“Crossover-Drug” Treatment for Drug Eluting Coronary Stent In-Stent
Restenosis in a Large Animal Model
Serge D. Rousselle1, Yan Li2, Chris Barry2, Javier A. Garza1, Armando Tellez1
1Alizée Pathology, LLC, Thurmont, MD, 2Lutonix, Inc, New Hope, MN
Background: DES in-stent restenosis (ISR) is a more complex issue compared to
BMS-ISR. Paclitaxel coated balloons (PCB) are available as an option for DES-ISR
treatment. We aim to evaluate the vascular response to Lutonix PCB as treatment of a
same drug DES-ISR (Paclitaxel) and cross-over drug DES-ISR (-Limus) in a large
animal coronary ISR model.
Methods: 24 DES (8 EES: XIENCE PRO, 8 ZES: Resolute Integrity and 8 PES:
Taxus Liberte) were implanted in naïve porcine coronary arteries at a 1:1.3 over-
stretch. At 30 days post DES deployment all stents were randomized to either Lutonix
PCB (EES/PCB [T1]; ZES/PCB [T2]; PES/PCB [T3]) or POBA (EES/POBA [T4];
ZES/PCB [T5]; PES/PCB [T6]) treatment and they were followed for additional 30
days. Morphometry and safety parameters were assessed by histopathology by a semi-
quantitative score (0¼ not present-4¼overwhelmingly present).
Results: DCB treatment groups display a similar larger lumen area (T1¼5.83.2mm;
T2¼6.32.6mm; T3¼6.11.3) compared to POBA treatment (T4¼5.43.3mm;
T5¼6.12.8mm; T6¼5.92.4mm). Neotintimal area was reduced in the DCB treat-
ment group (T1¼2.90.8; T2¼2.61.3; T3¼3.22.2) compared to POBA groups
(T4¼3.92.1; T5¼4.12; T6¼3.93.5). In histology, similar degree of inﬂammation
was observed among PCB treatment groups (T1¼1.91.5; T2¼1.31.1; T3¼1.91.7)
compared to a slight higher inﬂammatory scores in the POBA treatment groups
(T4¼21; T5¼1.81.2; T6¼2.21). Fibrin deposition was low in all groups
(T1¼0.90.4; T2¼0.60.3; T4¼0.70.9; T5¼0.40.5), however when PES was used
the ﬁbrin score was slightly higher (T3¼1.30.9; T6¼10.5). Complete endothelial
coverage was observed in all treated groups (T1¼3.50.4; T2¼3.80.5; T3¼3.330.8;JACC Vol 64/11/Suppl B j September 13–17, 2014 j TCT Abstracts/DrT4¼3.750.3; T5¼40; T6¼3.90.2). The neointima hypocellularity was assessed
showing a similar low score (T1¼10.86; T2¼0.50.8; T3¼1.51; T4¼0.61.2;
T5¼00; T6¼10.3). All treatment groups showed an extremely low thrombosis
score (T1¼0.10.2; T2¼00, T3¼0.20.3; T4¼0.10.2; T5¼00; T6¼00).
Conclusions: Lutonix PCB, in a “cross-over” or “same drug” treatment, seem to be a
safe strategy for DES-ISR without signiﬁcantly increasing inﬂammation or ﬁbrin
deposition in a large animal preclinical model.
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First in Vivo Evaluation of Efﬁcacy of a Novel Peripheral Drug-Coated Balloon
in a Familial Hypercholesterolemic Swine Model of In-Stent Restenosis
Carlos A. Gongora1, Masahiko Shibuya1, Barbara A. Huibregtse2, Jenn McGregor1,
Yanping Cheng1, Gerard B. Conditt1, Geng-Hua Yi1, Greg L. Kaluza1,
Juan Granada1
1Cardiovascular Research Foundation, Orangeburg, NY, 2Boston Scientiﬁc,
Marlborough, MA
Background: Drug coated balloons (DCBs) employ different coating technologies to
deliver the antirestenotic drug without permanent polymer carrier. The ideal formu-
lation should maximize the neointimal inhibition with the least drug possible, while
ensuring adequate healing and containing the particulate release from the coating. We
evaluated the efﬁcacy of a novel drug coated balloon technology with two clinically
proven DCBs and an uncoated balloon control group in a familial hypercholesterol-
emic swine (FHS) model.
Methods: Twenty four peripheral arteries of 6 FHS were injured at day 0 with an
uncoated balloon, followed by implantation of self-expanding stents in the injured
segments. At day 14, the in-stent restenosis sites were treated with two clinically
proven DCB (In.Pact Paciﬁc Medtronic , 3 ug/mm2 n¼6), and (Lutonix BARD, 2
ug/mm2 n¼6), a novel DCB (Ranger Boston Scientiﬁc, 2 ug/mm2 n¼6), and an
uncoated balloon control (Sterling, Boston Scientiﬁc, n¼6). At day 0, 14 and 42
quantitative vascular analysis and histology at terminatio.
Results: The difference (D) in angiographic percentage diameter stenosis between day
14 and day 42 showed signiﬁcant inhibition of neointimal proliferation with smaller
deltas from baseline in the DCB groups when compared to control (Control: D60%,
Ranger: D10%, InPact: D5%, Lutonix: D10%). The histological data also showed less
neointima and percentage area of stenosis in all DCB groups. Fibrin, a characteristic
hallmark of paclitaxel in arterial tissue, was equivalent in all DCBs and twice as high
as in control. Ranger DCB showed a slightly higher endothelialization score than
In.Pact (Control: 30, Ranger: 2.570.34, In.Pact: 1.850.55, Lutonix: 2.520.35,
p¼< 0.05), and In.Pact had the lowest score of neointima maturity (Control:
2.90.11, Ranger: 1.870.66, In.Pact: 1.480.74, Lutonix: 1.880.49, p¼< 0.05).
Conclusions: All DCBs showed signiﬁcant inhibition of neointimal formation when
compared to the uncoated balloon control. The In.Pact DCB provided strongest
neointimal inhibition but less complete healing. The Ranger DCB provided satisfac-
tory neointimal inhibition and a slightly better healing when compared to In.Pact.
TCT-289
Detection of Paclitaxel Contamination Resulting from the Simulated Clinical Use
of Drug Coated Balloon Catheters
Charisse Ward1, Carlos I. Mena1
1Yale University, New Haven, CT
Background: Coating robustness and durability are important characteristics of the
DCB design. Drug that is not ﬁrmly adhering on the balloon surface falls off and could
potentially lead to paclitaxel contamination of work surfaces in the catheterization lab
and expose lab personnel to a toxic chemotherapeutic agent.
Methods: This study sought to determine the coating durability of the Lutonix drug
coated balloon compared to the Medtronic drug coated balloon and to evaluate the
amount of paclitaxel that does not adhere to the balloon and is transferred to work
surfaces during simulated clinical procedural handling. A swab method in the Che-
moGLO kit was used for quantifying trace amount of drug on surface. Both the
Medtronic devices and the Lutonix devices were evaluated in a simulated clinical use
study by three independent physicians at three hospitals. After each physician per-
formed the simulated clinical use test, the surfaces where paclitaxel could have fallen
were swabbed and analyzed for paclitaxel by HPLC (LLQ is 0.01ng/cm2.) The person
performed the swabbing was blinded to the testing devices.
Results: The paclitaxel analysis results from this study and statistical analysis are
summarized on table 1.The ANOVA analysis indicates that paclitaxel surface con-
centrations of the Lutonix devices and the Medtronic devices are statistically different.Conclusions: This study revealed 15 out of 18 Medtronic devices were over the
decontamination level, none of the 21 Lutonix devices was over the decontamination
level. Precautions to avoid working place drug contamination may be required for
handling the Medtronic drug coated balloon catheters. Drug decontamination is rec-
ommended after each time use of the Medtronic DCB catheters to ensure the drug
surface concentration is below 1ng/cm2.ug-Eluting Balloons and Local Drug Delivery B83
